2.Three Cases of Mirtazapine Induced Akathisia.
Seung Hwan LEE ; Min NAM ; Young Cho CHUNG
Journal of the Korean Society of Biological Psychiatry 2001;8(1):162-166
The mirtazapine is a relatively new antidepressant that has noradrenergic and specific serotonin antagonist action(NaSSAs). This has been known as one of the most safest drugs because of its few side effects. Until now, there have been only one case report that mirtazapine causes a EPS side effect(restless leg syndrome). But the peculiar mechanism of this drug makes it impossible to explain the exact reasons why the mirtazapine could induce EPS symptoms. Authors obseved three cases of mirtazapine indeced akathisia. We could not explain the phenomenon the other way except akathisia. So here we presents the three case of mirtazapine induced akathisia and a few possible hypothesis of this phenomenon.
Leg
;
Psychomotor Agitation*
;
Serotonin
3.Management Dilemma in Olanzapine Induced Restlessness and Cramps in Legs.
Clinical Psychopharmacology and Neuroscience 2017;15(1):87-88
No abstract available.
Leg*
;
Muscle Cramp*
;
Psychomotor Agitation*
4.The Effect of Cyproheptadine Treatment in Neuroleptic Induced Akathisia.
Dong Seon CHUNG ; In Joon PARK ; Young Joon KWON ; Hee Yeon JUNG ; Sun Ho HAN
Journal of Korean Neuropsychiatric Association 1997;36(5):935-941
OBJECTIVE: Neuroleptic Induced Akathisia(NIA) often occurs in neuroleptic treated patients. Cyproheptadine, an antiserotonergic agent, was used to treat neuroleptic induced akathisia. METHOD: In an open trial 21 neuroleptic-treated patients with akathisia were administrated Cyproheptadine(16mg/day) over 4 days. Assessment of akathisia was evaluated using Barnes' rating scale(BAS) for neuroleptic induced akathisia. The degree of depression and psychosis were assessed by brief psychiatric rating scale(BFRS) and Hamilton rating scale for depression(HAM-D). RESULT: Most patients(20 of 21) with neuroleptic induced akathisia(NIA) showed improvement under the treatment of cyproheptadine. There was no aggravation of psychosis or depression during the treatment. Symptoms of akathisia aggravated when cyproheptadine was discontinued. CONCLUSION: Cyproheptadine may be useful in the treatment of neuroleptic induced akathisia(NIA).
Cyproheptadine*
;
Depression
;
Humans
;
Psychomotor Agitation*
;
Psychotic Disorders
5.A Study on Depression in College Students.
Jong Bum LEE ; Byung Tak PARK ; Sung Douk CHEUNG ; Jong Hak CHUNG
Yeungnam University Journal of Medicine 1985;2(1):123-132
The authors studied depression in 5,869 college students (male: 3,893, female: 1,976) using Zung's Self-Rating Depression Scale (SDS). The results are as follows: 1) Female college students showed significantly higher total depression scores than male college students (p<0.001). 2) The items of confusion, indecisiveness, and psychomotor retardation were scored higher in both groups and the items of suicidal rumination, psychomotor agitation, constipation and tachycardia were scored lower in both groups. 3) 18.2% of male college students showed rather serious depression level of score 50 or higher, while 33.1% of female college students showed the same scores. 4) The psychosocial factors relating to pessimistic views to past, present & future self-images showed significantly high depression scores. 5) The depression items of fatigue, anxiousness, tachycardia, apprehension, fear, and body aches & pain were correlated significantly over 0.40 of correlation coefficient.
Constipation
;
Depression*
;
Fatigue
;
Female
;
Humans
;
Male
;
Psychology
;
Psychomotor Agitation
;
Tachycardia
6.Development of the Korean Form of Zung's Self-Rating Depression Scale.
Yeungnam University Journal of Medicine 1995;12(2):292-305
This study was carried out to develop a Korean language version of Zung's self-rating depression scale (SDS). The subjects consisted of 173 males and 161 females drawn from various groups of the general population by a cluster of sampling methods. In order to analyze the data on depression scores, Pearson's product moment correlation coefficient method was carried .out, as well as reliability and factor analysis, by the SPSS/PC+ program. The results obtained were as follows: The mean average of the total depression scores were 40.60. 8.66 for the subjects. Thirty-seven subjects (11.1%) showed high depression scores of 50 or over. Test-retest reliability(coefficient r=0.82, p <0.001), internal consistency(coefficient r=0.84, p <0.001) were satisfactory. Factor analysis using oblique technique rotation yielded five factors. The items of confusion, indecisiveness, decreased libido, diurnal variation, and psychomotor retardation were scored higher by the subjects. The items of suicidal rumination, psychomotor agitation, constipation, irritability, and weight loss were scored lower.
Constipation
;
Depression*
;
Female
;
Humans
;
Libido
;
Male
;
Psychomotor Agitation
;
Weight Loss
7.Comparison of the Clinical Efficacy and Safety between Intramuscular Olanzapine and Intramuscular Haloperidol Injection in the Treatment of Delirium.
Hyun Kook LIM ; In Ho PAIK ; Keun OH ; Chang Uk LEE ; Chul LEE
Korean Journal of Psychopharmacology 2007;18(6):423-428
OBJECTIVE: The present study aimed to provide preliminary data on the effectiveness and tolerability of intramuscular (IM) olanzapine and IM haloperidol for patients with delirium. METHODS: Sixty-two patients with delirium were randomly assigned to either olanzapine IM or haloperidol IM groups, with a flexible dosing schedule for 7 days. The Delirium Rating Scale-revised-98 (DRS-R-98), clinical global impression-severity (CGI-S) were assessed daily. The Simpson-Angus Rating Scale (SAS), the Barnes Akathisia Rating Scale (BARS) and the Abnormal Involuntary Movement Scale (AIMS) were used for the assessments of side effects. RESULTS: The DRS-R-98 scores were significantly decreased over time (F=26.02, P<0.0001), without any significant group differences (F=0.048, P=0.829), and time by treatment group interaction (F=5.64, P=0.725). There were no serious adverse events in both groups. The scores on the SAS, BARS, and AIMS were not changed significantly during the study. CONCLUSIONS: This study showed that olanzapine IM did not show any superior efficay and safety compared with haloperidol IM in treatment delirium. However our study suggested that either olanzapine IM or haloperidol IM would be effective and tolerable. Adequately powered studies with a head-to-head comparison design will be mandatory to draw any definite conclusion.
Appointments and Schedules
;
Delirium*
;
Dyskinesias
;
Haloperidol*
;
Humans
;
Psychomotor Agitation
8.Comparison of the Clinical Efficacy and Safety between Intramuscular Olanzapine and Intramuscular Haloperidol Injection in the Treatment of Delirium.
Hyun Kook LIM ; In Ho PAIK ; Keun OH ; Chang Uk LEE ; Chul LEE
Korean Journal of Psychopharmacology 2007;18(6):423-428
OBJECTIVE: The present study aimed to provide preliminary data on the effectiveness and tolerability of intramuscular (IM) olanzapine and IM haloperidol for patients with delirium. METHODS: Sixty-two patients with delirium were randomly assigned to either olanzapine IM or haloperidol IM groups, with a flexible dosing schedule for 7 days. The Delirium Rating Scale-revised-98 (DRS-R-98), clinical global impression-severity (CGI-S) were assessed daily. The Simpson-Angus Rating Scale (SAS), the Barnes Akathisia Rating Scale (BARS) and the Abnormal Involuntary Movement Scale (AIMS) were used for the assessments of side effects. RESULTS: The DRS-R-98 scores were significantly decreased over time (F=26.02, P<0.0001), without any significant group differences (F=0.048, P=0.829), and time by treatment group interaction (F=5.64, P=0.725). There were no serious adverse events in both groups. The scores on the SAS, BARS, and AIMS were not changed significantly during the study. CONCLUSIONS: This study showed that olanzapine IM did not show any superior efficay and safety compared with haloperidol IM in treatment delirium. However our study suggested that either olanzapine IM or haloperidol IM would be effective and tolerable. Adequately powered studies with a head-to-head comparison design will be mandatory to draw any definite conclusion.
Appointments and Schedules
;
Delirium*
;
Dyskinesias
;
Haloperidol*
;
Humans
;
Psychomotor Agitation
9.There Cases of Extrapyramidal Symptoms Following Fluoxetine.
Min NAM ; In Kwa JUNG ; Dong ll KWAK ; Gi Chul LEE ; Jung Ho LEE
Journal of Korean Neuropsychiatric Association 1997;36(2):376-383
The selective serotonin reuptake inhibitor fluoxetine is one of the most frequently prescribed drugs for the treatment of depression and other psychiatric disorders. In the few years, there have been several reports of adverse effects encountered during coadministration of fluoxetine with or without other psychotropic drugs. We experienced three cases of extrapyamidal symptoms were developed when administered fluoxetine alone and with neuroleptics. We conclude that there is a probable or possible causal relationship between fluoxetine and extrapyramidal side effects. The pathogenesis of such adverse reactions, which may be hetero-geneous, is unknown, but it has been suggested that they might be caused by serotonergically mediated inhibition of dopaminergic transmission. From reports in those cases, it appears that fluoxetine alone may be associated with extrapyramidal side reactions. Furthermore the potential for increased levels of concomitant psychotropic medicines and increased side effects, should be borne in mind.
Antipsychotic Agents
;
Depression
;
Fluoxetine*
;
Psychomotor Agitation
;
Psychotropic Drugs
;
Serotonin
10.Add-On Therapy of Quetiapine for Bipolar Disorder: A 6 Month, Prospective Trial.
Chi Un PAE ; Tae Suk KIM ; Young Ji LEE ; Jung Jin KIM ; Soo Jung LEE ; Chang Uk LEE ; Chul LEE ; In Ho PAIK
Korean Journal of Psychopharmacology 2005;16(4):279-284
OBJECTIVES: This study was conducted to evaluate the overall effectiveness and tolerability of adjunctive quetiapine in the long-term treatment of bipolar disorder as a continuation therapy. METHODS: Twenty-three bipolar I patients participated and required to have quetiapine add-on treatment in combination with existing or new mood stabilizers. Clinical assessment was carried out using Young Mania Rating Scale (YMRS), Clinical Global Impression (CGI), Hamilton Depression Rating Scale-17 item, Simpson-Angus Rating Scale and Barnes Akathisia Rating Scale at baseline, 1, 4, 12 and 24 weeks. RESULTS: The YMRS and CGI decreased significantly from baseline to endpoint by 89.7% and 78.3%, respectively (p<0.0001 ; p<0.0001). Twenty-two patients exhibited at least 50% improvement on YMRS score by the end of the study. CONCLUSION: This study suggests that quetiapine may hold a promise as an adjunct in the long-term treatment of bipolar disorder.
Bipolar Disorder*
;
Depression
;
Humans
;
Prospective Studies*
;
Psychomotor Agitation
;
Quetiapine Fumarate